SS Innovations Reports First Quarter 2025 Financial Results

Rhea-AI Summary

SS Innovations (NASDAQ: SSII) reported strong Q1 2025 financial results with record quarterly revenue of $5.1 million, up 40.8% year-over-year. The growth was driven by increased sales of their SSi Mantra 3 surgical robotic system. Key highlights include: - 15 new system installations (66.7% increase YoY) - Gross margin expanded to 21.23% - Net loss improved to $5.7 million ($0.03/share) vs $9.8 million ($0.06/share) in Q1 2024 - Cumulative installed base reached 78 units with 3,568 total surgeries performed - Cash position of $15.9 million with zero long-term debt The company achieved a significant milestone with its Nasdaq uplisting in April 2025 and plans to submit a De Novo FDA application for SSi Mantra 3 by July 2025, while pursuing EU CE Mark approval by late 2025.

Positive

• Record quarterly revenue of $5.1M, up 40.8% YoY
• 67% increase in system installations (15 vs 9 in Q1 2024)
• Improved gross margin to 21.23% from 20.02%
• Reduced net loss by 41.8% to $5.7M from $9.8M
• Strong cash position of $15.9M with zero long-term debt
• Successful Nasdaq uplisting in April 2025
• New regulatory approvals in Philippines and Ukraine
• 302.7% growth in instrument sales revenue

Negative

• Still operating at a significant net loss of $5.7M
• Relatively low gross margin at 21.23% despite improvement
• FDA and EU approvals still pending for major market expansion

Insights

Medical Technology Financial Analyst

SS Innovations delivered 41% revenue growth with expanded installations, reduced losses, and progressing FDA plans, indicating positive momentum.

SS Innovations has posted a 40.8% year-over-year revenue increase to $5.1 million in Q1 2025, primarily driven by a 28.8% growth in system sales of their SSi Mantra 3 surgical robotic system. This performance demonstrates robust commercial traction, with quarterly installations jumping 66.7% from 9 to 15 units compared to Q1 2024.

What's particularly encouraging is the revenue diversification pattern. While system sales remain the primary growth driver, instrument sales surged by 302.7% and warranty revenue grew by an impressive 1,202.3%, albeit from a small base. This suggests the developing annuity revenue streams typical of successful medical device business models – where the initial system placement creates recurring revenue opportunities through consumables and service contracts.

The company is also demonstrating operational improvement with gross margin expanding by 121 basis points to 21.23%, attributed to reduced raw material costs. The net loss narrowed significantly from $9.8 million to $5.7 million, representing a 41.8% reduction in losses while maintaining growth investments.

The cumulative installed base has more than tripled year-over-year to 78 systems, with total procedures reaching 3,568 – a 264% increase. This acceleration in procedure volume outpacing installed base growth indicates improving utilization rates, a critical metric for robotic surgery adoption.

From a regulatory standpoint, SS Innovations is targeting a July 2025 De Novo FDA application, which would open access to the lucrative US market. Combined with EU market pursuit and recent approvals in two additional countries, the company is executing a methodical global expansion strategy backed by a $15.9 million cash position and zero long-term debt.

The Nasdaq uplisting completed in April represents a significant milestone that should improve liquidity and institutional investor access. While still operating at a loss, the company appears to be on a path toward improving unit economics as scale increases.

Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales
On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3  

FORT LAUDERDALE, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three months ended March 31, 2025.   The Company also filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, with the Securities and Exchange Commission on May 14, 2025.

First Quarter 2025 Overview

• Revenue increased 40.8% to $5.1 million from $3.6 million in the first quarter of 2024.
• Gross margin expanded 121 basis points to 21.23% from 20.02% in the first quarter of 2024.
• Gross profit rose 49.3% to $1.1 million from $0.7 million in the first quarter of 2024.
• Net loss of $5.7 million, or $(0.03) per diluted share, compared to net loss of $9.8 million, or $(0.06) per diluted share, in the first quarter of 2024.
• SSi Mantra surgical robotic system installations totaled 15, up 66.7% from 9 installations in the first quarter of 2024.

As of March 31, 2025

• Long-term debt of $0.
• Cash and cash equivalents totaled $15.9 million, excluding restricted cash.
• SSi Mantra cumulative installed base totaled 78 and cumulative surgeries reached 3,568.
  

Subsequent Events

• On April 25, 2025, the Company’s common stock uplisted to The Nasdaq Capital Market®.

CEO Commentary
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “In the first quarter of 2025, we achieved record quarterly revenue of $5.1 million, up 40.8% from $3.6 million in the first quarter of 2024, driven by higher unit sales of our innovative, cutting-edge SSi Mantra 3 surgical robotic system to leading healthcare facilities in India and abroad. Our gross margin also improved during the quarter, primarily reflecting a reduction in raw material prices. With an expanding installed base and growing utilization of SSi Mantra 3 by medical professionals globally, SS Innovations is well positioned for continued robust organic growth during the remainder of the year.”

Dr. Srivastava continued, “After quarter end, we uplisted to Nasdaq, an exciting milestone that symbolizes a new chapter of global expansion for the Company. We intend to widen our presence beyond the seven countries where our SSi Mantra surgical robotic system has been cleared to market, with a focus on pursuing approval in the European Union and United States. We plan to submit a De Novo application for SSi Mantra to the U.S. Food and Drug Administration by the end of July 2025 for multiple indications and continue along the pathway towards a European Union CE Mark decision as soon as late 2025. Our vision is to decentralize and democratize robotic surgery by deploying our cost-effective, gold-standard SSi Mantra 3 devices across the globe for the benefit of a wider range of patients in need.”

Select Business Highlights in First Quarter 2025

• The SSi Mantra 3 surgical robotic system enabled the world’s first ever robotic cardiac telesurgery.
• The Company’s state-of-the-art mobile telesurgery unit debuted in India with the aim of improving remote surgical access.
• The SSi Mantra 3 received medical device regulatory approvals in the Philippines and Ukraine.
  

Revenue Breakdown and Summary of Installations / Surgeries

Category	Q1 2024		Q1 2025		Variance		Percentage
System sales	$3,494,759		$4,502,482		$1,007,723		28.8	%
Instrument sales		118,515		477,208		358,693	302.7	%
Warranty sales		9,407		122,504		113,097	1,202.3	%
Lease income		15,012		18,416		3,404	22.7	%
Total revenue	$3,637,693		$5,120,610		$1,482,917		40.8	%
SSi Mantra installations		9		15		6	67	%
Cumulative installed base1		24		78		54	225	%
SSi Mantra surgeries		361		787		426	118	%
Cumulative surgeries1		981		3,568		2,587	264	%
1 at period end

About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.

About the SSi Mantra
The SSi Mantra Surgical Robotic System is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.

Forward-Looking Statements – Safe Harbor
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations International’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Investor Contact:
The Equity Group        
Kalle Ahl, CFA                
T: (303) 953-9878        
kahl@equityny.com

Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@equityny.com

Media Contact:
press@ssinnovations.org
T: (212) 739-0300

SS INNOVATIONS INTERNATIONAL, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
			As of
			March 31, 2025				December 31, 2024
ASSETS
Current Assets:
Cash and cash equivalents			$	15,873,217			$	466,500
Restricted cash				5,886,589				5,838,508
Accounts receivable, net				3,962,202				4,466,047
Inventory, net				14,295,141				10,206,898
Prepaids and other current assets				7,602,794				6,438,338
Total Current Assets				47,619,943				27,416,291
Non- Current Assets:
Property, plant, and equipment, net				7,044,307				5,385,955
Right of use asset				2,629,225				2,623,880
Accounts receivable, net				2,818,043				3,299,032
Restricted cash- Non current				318,982				318,527
Prepaids and other non current assets				3,026,461				3,341,528
Total Non-Current Assets				15,837,018				14,968,922
Total Assets			$	63,456,961			$	42,385,213
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY
Current Liabilities
Bank overdraft facility			$	7,682,411			$	7,994,906
Notes payable				-				7,450,000
Current portion of operating lease liabilities				368,309				409,518
Accounts payable				3,641,410				2,312,382
Deferred revenue				1,871,275				1,278,602
Accrued expenses & other current liabilities				1,433,308				1,884,814
Total Current Liabilities				14,996,713				21,330,222
Non- Current Liabilities
Operating lease liabilities, less current portion				2,402,653				2,349,118
Deferred Revenue- Non Current				5,405,227				5,173,953
Other non current liabilities				98,078				74,817
Total Non-Current Liabilities				7,905,958				7,597,888
Total Liabilities			$	22,902,671			$	28,928,110
Stockholders’ equity:
Preferred stock, authorized 5,000,000 shares of Series A, Non-Convertible Preferred Stock, $0.0001 par value per share;  1,000 shares issued and outstanding as of March 31, 2025 and December 31, 2024				1				1
Common stock,  250,000,000 shares authorized, $0.0001 par value, 193,556,177 shares and 171,579,284 shares issued and outstanding as of March 31, 2025 and December 31, 2024 respectively				19,354				17,157
Accumulated other comprehensive income (loss)				(726,911	)			(749,625	)
Additional paid in capital				89,705,829				56,952,200
Capital reserve				899,917				899,917
Accumulated deficit				(49,343,900	)			(43,662,547	)
Total stockholders’ equity				40,554,290				13,457,103
Total liabilities and stockholders’ equity			$	63,456,961			$	42,385,213

SS INNOVATIONS INTERNATIONAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)
			For The Three months ended
			March 31, 2025				March 31, 2024
REVENUES
System sales				4,502,482				3,494,759
Instruments sale				477,208				118,515
Warranty sale				122,504				9,407
Lease income				18,416				15,012
Total revenue			$	5,120,610			$	3,637,693
Cost of revenue				(4,033,402	)			(2,909,511	)
GROSS PROFIT				1,087,208				728,182
OPERATING EXPENSES:
Research & development expense				1,010,095				527,991
Stock compensation expense				2,379,212				7,108,750
Depreciation and amortization expense				208,882				80,101
Selling, general and administrative expense				3,410,872				2,843,659
TOTAL OPERATING EXPENSES				7,009,061				10,560,501
Loss from operations				(5,921,853	)			(9,832,319	)
OTHER INCOME (EXPENSE):
Interest Expense				(379,905	)			(190,088	)
Interest and other income, net				620,405				180,654
TOTAL OTHER INCOME (EXPENSE), NET				240,500				(9,434	)
LOSS BEFORE INCOME TAXES				(5,681,353	)			(9,841,753	)
Income tax expense				-				-
NET LOSS			$	(5,681,353	)		$	(9,841,753	)
Net loss per share - basic and diluted			$	(0.03	)		$	(0.06	)
Weighted average- basic shares				178,836,342				170,729,490
Weighted average- diluted shares				188,599,859				181,609,691
CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS
NET LOSS			$	(5,681,353	)		$	(9,841,753	)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation gain/(loss)				6,876				(79,314	)
Retirement Benefit (net of tax)				15,838				8,507
TOTAL COMPREHENSIVE LOSS			$	(5,658,639	)		$	(9,912,560	)

SS INNOVATIONS INTERNATIONAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
		For The Three months ended
		March 31, 2025				March 31, 2024
Cash flows from operating activities:
Net loss		$	(5,681,353	)		$	(9,841,753	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			208,882				80,101
Operating lease expense			205,275				178,871
Interest Expense			155,015				283,868
Interest and other income, net			(140,928	)			(168,746	)
(Reversal of) / Provision for credit loss reserve			(422,711	)			389,330
Stock compensation expense			2,379,212				7,108,750
Changes in operating assets and liabilities:
Accounts receivable, net			1,275,750				(3,186,108	)
Inventory, net			(5,082,673	)			(1,326,859	)
Deferred revenue			823,947				2,290,417
Prepaids and other assets			(1,003,604	)			56,511
Accounts payable			1,329,028				926,083
Accrued expenses & other liabilities			48,331				705,455
Operating lease payment			(197,545	)			(167,838	)
Net cash used in operating activities			(6,103,374	)			(2,671,918	)
Cash flows from investing activities:
Purchase of property, plant and equipment			(872,804	)			(127,255	)
Net cash used in investing activities			(872,804	)			(127,255	)
Cash flows from financing activities:
Proceeds from bank overdraft facility (net)			(312,495	)			188,259
Proceeds from issuance of convertible notes to principal shareholder			28,000,000				1,000,000
Proceeds from issuance of convertible notes to other investors			-				1,450,000
Repayment of convertible notes to principal shareholder, including interest			(4,212,637	)			-
Repayment of convertible notes to other investors, including interest			(1,068,849	)			-
Net cash provided by financing activities			22,406,019				2,638,259
Net change in cash			15,429,841				(160,914	)
Effect of exchange rate on cash			25,412				(31,351	)
Cash and cash equivalents at the beginning of the period			6,623,535				7,087,845
Cash and cash equivalents at end of the period		$	22,078,788			$	6,895,580
Supplemental disclosure of cash flow information:
Conversion of convertible notes into common stock, including interest		$	30,645,360			$	-
Transfer of systems from inventory to property, plant and equipment		$	994,430			$	1,422,880

FAQ

What were SSII's Q1 2025 financial results?

SS Innovations reported Q1 2025 revenue of $5.1M (up 40.8% YoY), gross margin of 21.23%, and net loss of $5.7M ($0.03 per share). The company installed 15 new SSi Mantra systems and maintained $15.9M in cash with no long-term debt.

How many SSi Mantra surgical systems has SSII installed to date?

As of March 31, 2025, SS Innovations has a cumulative installed base of 78 SSi Mantra systems, which have performed 3,568 surgeries in total.

When will SSII submit FDA application for SSi Mantra 3?

SS Innovations plans to submit a De Novo application to the FDA for SSi Mantra 3 by the end of July 2025.

What was SSII's revenue growth in Q1 2025?

SSII's revenue grew 40.8% year-over-year to $5.1 million in Q1 2025, compared to $3.6 million in Q1 2024.

How much cash does SSII have on hand?

As of March 31, 2025, SS Innovations had $15.9 million in cash and cash equivalents, excluding restricted cash, with zero long-term debt.